Radiation Oncology
Radiation therapy-associated toxicity: Etiology, management, and prevention.
15 Jul, 2021 | 09:13h | UTC
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
1 Jul, 2021 | 09:44h | UTC
Commentary on Twitter
Now available in Annals of Oncology, the @myESMO clinical practice guidelines for the diagnosis, treatment and follow-up of anal cancer, a rare disease accounting for less than 1% of all cancers https://t.co/usnFsd00BJ pic.twitter.com/bI0v60j8Ft
— Annals of Oncology (@Annals_Oncology) June 30, 2021
Randomized trial long-term results confirm the benefits of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer
20 May, 2021 | 08:16h | UTC
Commentaries on Twitter
Out at @ASCO_pubs
🔟yr Outcome of Neoadj #Chemoradiotherapy➕Surgery for #EsophagealCancer☑️Show OS benefit in locally advanced resectable esophageal or junctional #Cancer who receive preop chemorad🧪☢️ According to CROSS, persists at least🔟years‼️https://t.co/yJSibSveAh pic.twitter.com/UssnzuFiEe
— Gil Morgan (@weoncologists) May 14, 2021
Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists – 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck pic.twitter.com/2JwV0iOvoB
— ASCO Publications (@ASCO_pubs) May 5, 2021
RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.
10 May, 2021 | 00:46h | UTC18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link to abstract – $ for full-text)
Population-based cohort study suggests increased survival after breast conservation surgery + radiotherapy compared to mastectomy with or without radiotherapy in women with breast cancer.
10 May, 2021 | 00:42h | UTC
Commentary on Twitter
Women receiving breast-conserving surgery for #breastcancer fare better than those who take away the whole breast says a new study taking into account comorbidities and socioeconomic background. Superior survival rates support less extensive surgery https://t.co/JEXasP56Di
— JAMA Surgery (@JAMASurgery) May 5, 2021
Review: Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer
30 Apr, 2021 | 08:31h | UTC
M-A: Chemotherapy and radiotherapy in locally advanced head and neck cancer
15 Apr, 2021 | 06:29h | UTC
Commentary on Twitter
What is the best treatment in locally advanced HN Cancer?
Our latest individual patient data network meta-analysis available here for free @TheLancetOncol: https://t.co/UuFvjpKO6I
Many limitations but by far the largest work on the topic (115 RCT, 29000 pts).
#radonc #hncsm pic.twitter.com/eNYHbxsB4Q
— Pierre Blanchard, MD (@PBlanchardMD) April 14, 2021
RCT: No benefit from palliative radiotherapy after esophageal cancer stenting
18 Mar, 2021 | 08:52h | UTC
Cohort study: Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer
14 Mar, 2021 | 20:09h | UTCAssociation of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer – JAMA Oncology (free for a limited period)
Commentary on Twitter
Ablative RT to 98Gy biologically effective dose following multiagent induction therapy for locally advanced pancreatic cancer (LAPC) was safe & resulted in durable locoregional tumor control & favorable survival https://t.co/pLf52Tt6j0 #GICSM
— JAMA Oncology (@JAMAOnc) March 12, 2021
New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer
7 Mar, 2021 | 19:28h | UTCNews Release: New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer – World Health Organization
Technical Document: Technical specifications of radiotherapy equipment for cancer treatment
🆕 guidance on the procurement of radiotherapy equipment released today in collaboration with @iaeaorg, aims to improve access to this life-saving #cancer treatment option that is still lacking in many parts of the world 🌎🌍🌏
👉 https://t.co/fnR0q3DDMq pic.twitter.com/21SHSaQGy7
— World Health Organization (WHO) (@WHO) March 5, 2021
M-A: Local salvage therapies after radiotherapy for prostate cancer
3 Mar, 2021 | 08:06h | UTCA Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) – European Urology (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Pleased to share the results of our "MASTER" systematic review and meta-analysis of local salvage therapies for radioreccurent PCa @EUPlatinum https://t.co/23hy1UtNm5
— Amar Kishan (@AmarUKishan) December 11, 2020
RCT: Endoscopic surgery improves survival compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma
28 Feb, 2021 | 20:45h | UTC
Guidelines in the management of CNS tumors
23 Feb, 2021 | 01:09h | UTCGuidelines in the management of CNS tumors – Journal of Neuro-Oncology
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update
21 Feb, 2021 | 21:47h | UTC
RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer
15 Feb, 2021 | 00:29h | UTC[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today
RCT: Total Body Irradiation vs. Chemotherapy Conditioning in Childhood ALL
9 Feb, 2021 | 00:39h | UTCCommentary: TBI Beats Chemoconditioning for ALL Transplants in Children – Medscape (free registration required)
Commentary on Twitter
Total body irradiation or chemotherapy conditioning in childhood acute lymphoblastic leukemia (ALL) — outcomes suggest there's still a role for TBI https://t.co/ICTC0iEGN8 #leusm #pedonc #pedcsm #JCO pic.twitter.com/xARMBlSeni
— ASCO Publications (@ASCO_pubs) December 26, 2020
Radiation therapy for small-cell lung cancer: ASCO Guideline endorsement of an ASTRO Guideline
29 Jan, 2021 | 01:27h | UTC
ASCO Guideline Update: Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer
28 Jan, 2021 | 01:17h | UTC
Randomized trial: Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer
28 Jan, 2021 | 01:09h | UTC
Commentary on Twitter
🚨 POP-RT P3 RCT in @ASCO_pubs
High-risk prostate cancer & pelvic LN risk ≥20% ➡️
-Prostate only
-Pelvic RTIG-IMRT w/ SIB
-50 Gy/25 fxn to Pelvis
-68 Gy to P+SV⬆️bFFS 95% v 81%
⬆️DFS ~90% v 77%
⬆️DMFS 96% v 89%
✅Low S/Ehttps://t.co/r6YjqWl8Cr#pcsm #radonc #oncoalert pic.twitter.com/d9EL02edcd— Mudit Chowdhary MD (@DrChowdharyMD) January 27, 2021
Randomized trial: Ultra-hypofractionated vs. conventionally fractionated radiotherapy for prostate cancer
19 Jan, 2021 | 01:14h | UTCUltra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
CSCO and ASCO Guideline: Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma
15 Jan, 2021 | 08:14h | UTC
Randomized trial: Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) improve outcomes vs. traditional approach in locally advanced rectal cancer
12 Jan, 2021 | 01:12h | UTCShort-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
New online: phase 3 RAPIDO trial: Short-course #radiotherapy followed by #chemotherapy before total mesorectal excision (TME) vs standard of care in locally advanced #rectalcancer https://t.co/bTgUC6Lo39 #crcsm pic.twitter.com/Iu3HbQ1xjG
— The Lancet Oncology (@TheLancetOncol) December 8, 2020
Meta-analysis: Total neoadjuvant therapy vs. standard therapy in locally advanced rectal cancer
12 Jan, 2021 | 01:10h | UTCCommentaries: Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way AND Total Neoadjuvant Therapy Improves Rectal Cancer Pathologic Response – Physician’s Weekly
Related meta-analysis (just published): Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials – Cancers
Commentary on Twitter
Systematic review & meta-analysis finds total neoadjuvant therapy for locally adv. rectal cancer is associated with a doubling of pathologic complete response vs standard chemoradiation plus by adjuvant chemo. @anup_kasi @KUMedCenter @geriradonc @agrothey https://t.co/oRccCh5bEb
— JAMA Network Open (@JAMANetworkOpen) December 16, 2020
Randomized trial: Among patients with advanced rectal cancer, short-course radiotherapy followed by chemotherapy before total mesorectal excision reduces disease-related treatment failure compared to standard treatment
15 Dec, 2020 | 01:29h | UTC
Commentary on Twitter
New online: phase 3 RAPIDO trial: Short-course #radiotherapy followed by #chemotherapy before total mesorectal excision (TME) vs standard of care in locally advanced #rectalcancer https://t.co/bTgUC6Lo39 #crcsm pic.twitter.com/Iu3HbQ1xjG
— The Lancet Oncology (@TheLancetOncol) December 8, 2020
Short review: How to diagnose and manage radiation therapy cardiotoxicity
6 Dec, 2020 | 23:27h | UTCHow to Diagnose and Manage Radiation Cardiotoxicity – JACC: CardioOncology